Abstract
Early reports from immunotherapy trials conclude durable responses. Long-term data may indicate otherwise. Better delineation of clinical courses of long-term survivors will accelerate the discovery and application of biomarkers. Two pressing issues among those treated with anti–PD-1/PD-L1 are understanding whether responders can have therapy abbreviated and overcoming resistance in nonresponders.
See related article by Gauci et al., p. 946
- Received November 5, 2018.
- Revision received November 19, 2018.
- Accepted November 28, 2018.
- Published first December 3, 2018.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
February 2019
Volume 25, Issue 3
Volume 25, Issue 3
Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal
Jump to section
Advertisement